Cancer research is moving beyond static molecular profiling. The next step is to connect biomarkers, ctDNA, epigenetics, organoids and treatment response into functional translational workflows.
Precision oncology is no longer only about identifying molecular alterations. The real challenge is to understand which biological signals are clinically meaningful, which models can predict response and which workflows can guide better therapeutic decisions.
Across hepatocellular carcinoma, colorectal cancer and pancreatic cancer, Imperion’s programmes aim to connect serum biomarkers, ctDNA, epigenetics, organoid models, tissue biology and clinical trajectories into more functional translational systems.
This direction reflects a simple principle: better biological interpretation leads to better decisions.